Drugs / OPIGOLIX
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02867306 | Jul → Aug 2016 | rheumatoid arthritis | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02175407 | Apr → Jun 2014 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02106780 | Aug → Sep 2011 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02146742 | Jun → Aug 2011 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02368912 | Jun 2010 → Aug 2011 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02884635 | Sep 2016 → Oct 2017 | rheumatoid arthritis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT01767090 | Dec 2012 → May 2015 | endometriosis | Astellas Pharma Europe B.V. | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPIGOLIX | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989969 ↗ |
| Known as | ASP1707 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02106780 ↗ |
| Known as | Opigolixum | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989969 ↗ |
| Action | Inhibit | “Gonadotropin-releasing hormone receptor antagonist” CHEMBL3989969 ↗1“GnRH antagonist, ASP1707” PMID 31067329 ↗ May 2019 |
| Modality | Other / unclassified | “GnRH antagonist, ASP1707” PMID 31067329 ↗ May 2019 |
| Route | Oral | “Oral” NCT01767090 ↗ |
| Target | GNRHR | “Gonadotropin-releasing hormone receptor antagonist” CHEMBL3989969 ↗ |